Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2022 Results Earnings Conference Call May 9, 2022 8:00 AM ET

Company Participants

Paul Friedman - Chairman and Chief Executive Officer

Rebecca Taub - Founder, Chief Medical Officer and President of Research & Development

Remy Sukhija - Chief Commercial Officer

Alex Howarth - Chief Financial Officer

Stephen Harrison - M.D., Medical Director, Pinnacle Clinical Research

Conference Call Participants

Ritu Baral - Cowen

Thomas Smith - SVB Securities

Yasmeen Rahimi - Piper Sandler

Andrea Tan - Goldman Sachs

Liisa Bayko - Evercore ISI

Operator

Good day, ladies and gentlemen, and welcome to the Madrigal Pharmaceuticals First Quarter 2022 Conference Call. At this time, all participants are in a listen-only mode. Following the remarks from the company, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this call may be recorded.

I would now like to introduce your host for today's conference, Dr. Paul Friedman, Chairman and Chief Executive Officer of Madrigal. Dr. Friedman, you may begin.

Paul Friedman

Thank you. Good morning, and thanks to all of you for joining us on the call. Here's the fine print dealing with our forward-looking statements. Please see today's press release and our SEC filings for forward-looking statement and risk factor considerations associated with these statements and our business.

With me on today's call are Becky Taub, President of R&D and Chief Medical Officer; Remy Sukhija, Chief Commercial Officer; and Alex Howarth, Chief Financial Officer. We also have Dr. Stephen Harrison joining us to provide his perspective on the MAESTRO program updates we're announcing today.

This morning, we issued a press release outlining a number of important clinical development program updates, including the acceptance of 4 resmetirom abstracts as oral presentations at EASL's International Liver Congress next month. Additional positive data from the Phase 3 MAESTRO-NAFLD-1 study and a new outcomes trial that will evaluate resmetirom for the treatment of NASH patients with compensated cirrhosis. We also announced that Madrigal secured a term loan facility, which puts us in a strong financial position for the road ahead.

The decision to expand our clinical development program and raise additional capital reflects our conviction in the potential of resmetirom to be a transformational therapy for patients with NASH. The emerging data for MAESTRO-NAFLD-1safety study, including the results we're announcing today continue to support that conviction, and we look forward to sharing additional data in our late breaker presentation at EASL.